Navigation Links
Oncothyreon Reports First Quarter 2008 Financial Results
Date:5/7/2008

BELLEVUE, WA, May 7 /PRNewswire-FirstCall/ - Oncothyreon Inc. (Nasdaq: ONTY) (TSX: ONY) (the "Company") today reported a net loss of $5.1 million or $0.26 per basic and diluted share for the quarter ended March 31, 2008, compared with $4.7 million or $0.24 per basic and diluted share for the comparable period in 2007. All results are in U.S. dollars.

Total revenue was $2.0 million in the first quarter of 2008, compared to $0.2 million for the same period in 2007. The increase of $1.8 million reflects the increased sale of clinical trial material to Merck KGaA to support the Phase 3 trial of Stimuvax.

Expenses for the quarter ended March 31, 2008, were $7.1 million, compared with $4.8 million for the comparable period in 2007. The increase in operating expenses of $2.3 million resulted from an increase in manufacturing and sale of Stimuvax for the Phase 3 clinical trial of $2.1 million and an increase in general and administrative expense of $0.8 million arising from professional and consulting fees. Partially offsetting this increase were reductions in research and development expense and marketing and business development expense of $0.7 million and $0.5 million respectively.

As of March 31, 2008, Oncothyreon's cash, cash equivalents and short term investments were $16.5 million, compared to $24.2 million at the end of 2007, a decrease of $7.7 million, or 31.8 percent. Major contributors to the net change included $5.1 million used in operations, an increase in inventory and accounts receivable totaling $2.0 million and a decrease in accounts payable and accrued liabilities of $1.5 million.

Financial Guidance

Oncothyreon believes the following financial guidance to be correct as of the date provided. The Company is providing this guidance as a convenience to investors and assumes no obligation to update it.

Oncothyreon's financial guidance is unchanged from that reported with the Company's 2007 financial results. For
'/>"/>

SOURCE Oncothyreon Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related biology technology :

1. Oncothyreon files investigational new drug application for PX-866 oncology compound
2. Data for Oncothyreons PX-12 and PX-866 presented at AACR Annual Meeting
3. Oncothyreon announces data from multiple small molecule programs to be presented at American Association of Cancer Research Annual Meeting
4. Oncothyreon announces effectiveness of shelf registration statement
5. Oncothyreon announces issuance of patent for PX-867
6. Oncothyreon to present at upcoming investment conferences
7. Oncothyreon reports full year and fourth quarter 2007 financial results
8. Oncothyreon announces March 10th webcast of fourth quarter and full year financial results conference call
9. Oncothyreons PX-478 is effective in preclinical model of human lung cancer
10. Oncothyreon launches new corporate website
11. Oncothyreon to present at BIO CEO & Investor Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/2/2014)... -- Technology Applications International Corporation (the "Company" or "NUUU")(OTC BB: ... Inc. has signed an additional exclusive licensing agreement with ... Johnson Space Center in Houston , ... Charles J. Scimeca , NUUU,s ... latest, exclusive agreement with NASA. In addition to our ...
(Date:9/2/2014)... , Sept. 2, 2014 Orexigen Therapeutics, ... the U.S. Patent and Trademark Office (PTO) has issued ... being evaluated for weight loss. NB32 is a fixed-dose ... U.S. Patent No. 8,815,889 claims methods for ... bupropion. The patent expires in 2024. If NB32 is ...
(Date:9/2/2014)... Md. , Sept. 2, 2014  Synthetic ... novel anti-infective biologic and drug candidates targeting specific ... today positive results from its final preclinical toxicology ... Administration (FDA) guidance, this bridging study was required ... candidate designed to prevent the devastating effects of ...
(Date:9/2/2014)... , Sept. 2, 2014  Spherix Incorporated (SPEX) -- an ... monetization of intellectual property, today announced that the United ... to the Company in the month of August that ... The issued patents are: ... U.S.RE45,081 issued August 19, 2014; and , U.S.RE45,095 ...
Breaking Biology Technology:Technology Applications International Corporation Subsidiary Enters Into Additional Exclusive Agreement with NASA at a Signing Ceremony at the Johnson Space Center In Houston, Texas 2Technology Applications International Corporation Subsidiary Enters Into Additional Exclusive Agreement with NASA at a Signing Ceremony at the Johnson Space Center In Houston, Texas 3Orexigen Expands NB32 Intellectual Property Portfolio With New U.S. Patent 2Orexigen Expands NB32 Intellectual Property Portfolio With New U.S. Patent 3Orexigen Expands NB32 Intellectual Property Portfolio With New U.S. Patent 4Synthetic Biologics to Initiate Clinical Trials of SYN-004 in 4Q 2014 to Prevent Potentially Deadly C. difficile Infections 2Synthetic Biologics to Initiate Clinical Trials of SYN-004 in 4Q 2014 to Prevent Potentially Deadly C. difficile Infections 3Synthetic Biologics to Initiate Clinical Trials of SYN-004 in 4Q 2014 to Prevent Potentially Deadly C. difficile Infections 4Synthetic Biologics to Initiate Clinical Trials of SYN-004 in 4Q 2014 to Prevent Potentially Deadly C. difficile Infections 5United States Patent & Trademark Office Issues Three New Standard Essential Patents to Spherix 2
... 13 Proteon Therapeutics is,presenting new data ... potential of PRT-201 to enhance outcomes in ... (PAD). The,presentation, entitled, "Local Catheter-Directed Elastase Therapy: ... is being made at the 20th,annual Transcatheter ...
... CLARA, Calif., Oct. 13 WebLOQ, Inc., ... secure and compliant eBusiness and,data-in-motion communications, today ... the WebLOQ ePrivacy solution in their state-of-the-art,Monterey ... partner, the,Monterey Peninsula Surgery Center, and other ...
... SYDNEY, Australia, Oct. 13 /Xinhua-PRNewswire-FirstCall/ -- Pharmaxis,Ltd (AXS: ... Quarterly,Report to Shareholders on the afternoon of Wednesday ... teleconference the following morning to,review the quarter and ... on Thursday 16th October at 8.30am (Sydney),(Wednesday 15th ...
Cached Biology Technology:Proteon Therapeutics to Present New Data on PRT-201 at Transcatheter Cardiovascular Therapeutics (TCT) Annual Symposium in Washington, D.C., October 13, 2008 2Monterey Spine and Joint Deploys WebLOQ ePrivacy Solution for HIPAA Compliant Health Information Exchange 2Monterey Spine and Joint Deploys WebLOQ ePrivacy Solution for HIPAA Compliant Health Information Exchange 3
(Date:9/2/2014)... may have discovered a new way of harnessing lupus ... DNA repair. , The findings were published recently in ... study, led by James E. Hansen, M.D., assistant professor ... that cancer cells with deficient DNA repair mechanisms (or ... significantly more vulnerable to attack by lupus antibodies. , ...
(Date:9/2/2014)... true that digital distribution of media will have ... at least when file sizes are large. , ... Yale,s Journal of Industrial Ecology that ... consoles such as PlayStation3. Researchers found that Blu-ray ... gas emissions than game files downloaded over broadband ...
(Date:9/2/2014)... 2, 2014 In a new study that could ... Florida campus of The Scripps Research Institute (TSRI) have ... unique manufacturing sites for molecules that can treat a ... as a reaction vessel and a disease-causing defect as ... cell," said TSRI Professor Matthew Disney.,"Because the treatment is ...
Breaking Biology News(10 mins):Sabotage as therapy: Aiming lupus antibodies at vulnerable cancer cells 2Scripps Florida scientists make diseased cells synthesize their own drug 2
... theoretical price of having one's personal genome sequenced just ... $2.2 million, and the goal is to reduce the ... realistic. , The sharp drop is due to a ... (HMS) researchers Jay Shendure, Gregory Porreca, George Church, and ...
... form of a powerful painkiller for a quick and dangerous ... alarm as the number of people dying from an overdose ... than morphine, rises. , Addicts are misusing a clear patch ... into the bloodstream over the course of a few days, ...
... with a Global Information System will provide valuable information ... National Institute of Environmental Health Sciences (NIEHS), one of ... provide the most up-to-date data to public health and ... industry maps, as well as demographic information for local ...
Cached Biology News:A step toward the $1,000 personal genome using readily available lab equipment 2Prescription pain patch abuse blamed for increase in deaths 2Prescription pain patch abuse blamed for increase in deaths 3FDA approves child-friendly AIDS medicine 2
... High-throughput protein crystallography involves using many ... Screening (HTS). The liquid handling requirements are ... volume: traditional crystallography plates have 24 or ... of microliters. For higher throughput, the number ...
... Description: ,Kit containing Dermal Fibroblasts (Mouse/BalbC) ... as a long-term culture, and is guaranteed ... continuous growth from the date supplied, when ... Dermis, mouse/BalbC, embryonic day 18.5 ,Applications: ...
... designed for protein pull-down experiments ... binding proteins. An order of ... agarose beads with 10 nmol ... terminus of the alkyl chain; ...
Rabbit polyclonal to Staphylococcus Enterotoxin A (HRP) ( Abpromise for all tested applications)....
Biology Products: